230
Views
4
CrossRef citations to date
0
Altmetric
Original Article

Efficacy of Rituximab Treatment in Vogt-Koyanagi-Harada Disease Poorly Controlled by Traditional Immunosuppressive Treatment

, , , , , , ORCID Icon, ORCID Icon, , , , ORCID Icon & ORCID Icon show all
Pages 1303-1308 | Received 23 Nov 2020, Accepted 18 Jan 2021, Published online: 01 Apr 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Emmett T. Cunningham$suffix/text()$suffix/text(), Caleb Ng, Eric B Suhler & Derrick P. Smit. (2022) Rituximab for Ocular Inflammatory Disease. Ocular Immunology and Inflammation 30:6, pages 1300-1302.
Read now

Articles from other publishers (3)

Manuel Busto-Iglesias, Lorena Rodríguez-Martínez, Carmen Antía Rodríguez-Fernández, Jaime González-López, Miguel González-Barcia, Begoña de Domingo, Luis Rodríguez-Rodríguez, Anxo Fernández-Ferreiro & Cristina Mondelo-García. (2023) Perspectives of Therapeutic Drug Monitoring of Biological Agents in Non-Infectious Uveitis Treatment: A Review. Pharmaceutics 15:3, pages 766.
Crossref
Ioannis Papasavvas, Ilknur Tugal-Tutkun & Carl P. HerbortJr.Jr.. (2022) Mechanisms, Pathophysiology and Current Immunomodulatory/Immunosuppressive Therapy of Non-Infectious and/or Immune-Mediated Choroiditis. Pharmaceuticals 15:4, pages 398.
Crossref
Ahmed M. Abu El-Asrar, Jo Van Damme, Sofie Struyf & Ghislain Opdenakker. (2021) New Perspectives on the Immunopathogenesis and Treatment of Uveitis Associated With Vogt-Koyanagi-Harada Disease. Frontiers in Medicine 8.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.